Stay up to date on the peptide landscape. We track FDA regulatory changes, supplier and market developments, new research, and community trends and break it down in plain language for the research community. No pharma jargon, no clinic marketing, no hype.
Regulatory & Legal
A source-based fact check of viral claims that 14 of 19 Category 2 peptides were unbanned, including what is official and what still appears unverified.
via FDA primary pages + regulatory analysis
Read full articleRegulatory & Legal
A plain-language breakdown of FDA's February 2026 enforcement posture on non-FDA-approved GLP-1 products and research-only labeling mismatches.
via FDA primary-source announcements
Read full articleResearch & Science
A practical summary of recent trial-direction updates, expected milestones, and what they may mean for peptide research watchers.
via clinical trial coverage
Read more coming soon
Regulatory & Legal
Key policy and market shifts affecting how researchers track availability, sourcing reliability, and quality signals.
via FDA and policy reporting
Read more coming soon
Supplier & Market
An overview of evolving third-party testing expectations and how to interpret newer documentation patterns.
via lab testing and vendor reports
Read more coming soon
Community
A quick look at how platform moderation and channel policy updates are changing where peptide communities share information.
via community platform updates
Read more coming soon
The peptide landscape moves fast. Regulations shift, suppliers come and go, and new research lands constantly. Most peptide news is either pharma-focused industry coverage or clinic-driven marketing. PepPal curates the developments that matter to the research peptide community and translates them into plain language. We do not sell peptides. We build tools and publish information to help researchers stay informed.